Conference Dates
June 12 – 17, 2022
Abstract
Adenovirus vectors (AdV) present high safety and immunogenicity for drug development, allowing more and more vaccines to adopt this technology platform in recent years. Due to the current COVID-19 pandemic, the global demand for AdV has experienced significant growth. Therefore, to optimize the upstream process in order to obtain high yields, good quality and stable viral vectors, it becomes critical that processes are stable and easy to scale-up, which has become a key focus of pharmaceutical companies in the field.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Amélie Boulais, Lara Nascimento-Brooks, Shuangqing Yu, Zhicheng Cao, Li Hu, Shuren Feng, Jinlu Du, Cuiling Song, and Junjie Luo, "High Density HEK293T culture for high yield, high quality, stable adenoviral vector production in Ambr® 250 stirred tank reactors" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/127